



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

BEST AVAILABLE COPY

Signed

*Stephen Hardley*

Dated 9 December 2004

CERTIFIED COPY OF  
PRIORITY DOCUMENT

26-03-98 15:54

01159 552201

26/03 '98 THU 15:50 FAX 01159 552201

P.03

R-240

Job-974

003

ERIC POTTER CLARKSON




## Patents Form 1/77

Patents Act 1977  
(Rev 16)

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

26MARS 1998 E348690-1 002866  
PO1/7700 25.00,- 9806442.1

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

DUNW\18811GB

2. Patent application number

(The Patent Office will fill in this part)

26 MAR 1998

9806442.1

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

University of Dundee

Dundee DD1 4HN  
United KingdomPatents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

798207601

4. Title of the invention

ENZYME INHIBITION

5. Name of your agent (*if you have one*)ERIC POTTER CLARKSON  
PARK VIEW HOUSE  
58 THE ROPEWALK  
NOTTINGHAM  
NG1 5DDPatents ADP number (*if you know it*)

1305010

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number  
(*if you know it*)Date of filing  
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(*day / month / year*)8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer yes if:*

YES

- a) *any applicant named in part 3 is not an inventor, or*
  - b) *there is an inventor who is not named as an applicant, or*
  - c) *any named applicant is a corporate body*
- See note (d)*

### ENZYME INHIBITION

The present invention relates to enzyme inhibition, and in particular to the inhibition of an enzyme that we call asparaginyl endopeptidase which we  
5 have found is involved in processing antigens, particularly microbial  
antigens, by the immune system.

The immune response to protein antigens involves a large number of individual gene products, and new ones are still being discovered. In  
10 some cases the gene products were known *per se*, but not known to be involved in the immune response.

An immune response may be raised towards foreign antigens, for example, antigens associated with microorganisms, or the immune  
15 response may be caused by a response to a self antigen (autoimmunity). In either case, there exists the need for methods and means for modulating the immune system and how it responds to these foreign and self antigens.

Because proteins must be proteolytically processed (ie partially degraded) before the T cells of the immune system can respond, one set of proteins  
20 of importance in an immune response are proteolytic enzymes (proteases). It is typically proteolysed proteins (ie protein fragments) which are presented by antigen presenting cells on MHC Class I or Class II molecules.

25

Several different aspartic and cysteine proteases are thought to be involved in invariant chain and antigen processing (see, for example, Fineschi & Miller (1997) *Trends Biochem. Sci.* 22, 377-382; and Chapman (1998)

presentation of peptides on Class II MHC molecule-containing cells (and to substantially inhibit T cell activation).

An enzyme with AEP activity is readily able to cleave the substrate Z-Ala-  
5 Ala-Asn-7-(4-methyl)coumarylamide to release a fluorescent product,  
where Z is benzyloxy carbonyl.

By an "inhibitor of asparaginyl endopeptidase" we include any suitable  
inhibitor. The inhibitor may be a competitive inhibitor or it may be a non-  
10 competitive inhibitor. AEP is a cysteine protease and so inhibitors which chemically react with the active cysteine residue are suitable and are, typically, irreversible inhibitors. Other amino acid residues, such as histidine, may be present at the active site and inhibitors which react with any active site residue are suitable.

15 In one embodiment of the invention the AEP inhibitor is a competitive inhibitor. Typically, the competitive inhibitor is a peptide comprising an asparagine-containing peptide. Suitably, the peptide is a peptide comprising a known AEP cleavage site but which, because of its affinity  
20 for AEP can compete for another AEP cleavage site and substantially prevent cleavage at the said other cleavage site if present in sufficient concentration. Known cleavage sites for AEP in tetanus toxin are described in Chen *et al* (1997) *J. Biol. Chem.* 272, 8090-8098.

25 In a preferred embodiment of the invention the competitive inhibitor has the general structure  $(X_1)_p N(X_2)_q$  wherein  $X_1$  and  $X_2$  are amino acid residues, N is an asparagine residue, p is 3 to 6 and q is 1 to 3.

ninhydrin, trinitrobenzene sulphonic acid or isotin test procedures. Upon completion of synthesis, peptides are cleaved from the resin support with concomitant removal of side-chain protecting groups by treatment with 95% trifluoroacetic acid containing a 50% scavenger mix. Scavengers commonly used are ethanedithiol, phenol, anisole and water, the exact choice depending on the constituent amino acids of the peptide being synthesised. Trifluoroacetic acid is removed by evaporation *in vacuo*, with subsequent trituration with diethyl ether affording the crude peptide. Any scavengers present are removed by a simple extraction procedure which on lyophilisation of the aqueous phase affords the crude peptide free of scavengers. Reagents for peptide synthesis are generally available from Calbiochem-Novabiochem (UK) Ltd, Nottingham NG7 2QJ, UK. Purification may be effected by any one, or a combination of, techniques such as size exclusion chromatography, ion-exchange chromatography and (principally) reverse-phase high performance liquid chromatography. Analysis of peptides may be carried out using thin layer chromatography, reverse-phase high performance liquid chromatography, amino-acid analysis after acid hydrolysis and by fast atom bombardment (FAB) mass spectrometric analysis.

20

In a further embodiment, the inhibitor may be a non-competitive or irreversible inhibitor. AEP activity can be blocked by high concentrations of inhibitors which block all cysteine proteases and some serine proteases. However, it is particularly preferred that the inhibitors are selective for 25 AEP.

Generally, irreversible AEP inhibitors may be any of peptide aldehydes, peptide chloromethyl ketones, peptide fluoromethyl ketones, peptide

Typically, peptide aldehyde inhibitors have the structure:

Acetyl (or other blocking group)-X<sub>n</sub>-Asparaginal

5

where X is an amino acid residue and n is between 1 and 100, preferably between 1 and 50, more preferably between 1 and 10 and typically 2 to 6.

A suitable peptide aldehyde includes acetyl-alanyl-glutamyl-asparaginal.

10

Elastatinal blocks AEP activity; however a more specific variant, in which the C terminal amino residue is replaced by asparagine, may be useful.

Figure 4 shows the structures of some useful inhibitors.

15

Typically, peptide chloromethylketone inhibitors have the structure:

Acetyl (or other blocking group)-X<sub>n</sub>-asparaginyl-chloromethyl ketone where X and n are as above.

20

A suitable peptide includes acetyl-alanyl-glutamyl-asparaginyl-chloromethylketone and acetyl-tyrosyl-valyl-alanyl-asparaginyl-chloromethylketone (analogous to ICE protease inhibitor YVAD-cmk); see Figure 4 for further details.

25

Typically, peptide fluoromethylketone inhibitors have analogous structures to peptide chloromethylketone inhibitors except for the replacement of a chloro group with a fluoro group.

It will be appreciated from the foregoing that AEP inhibitors may be designed based on other cysteine protease inhibitors such as E-64 (1-trans-epoxysuccinyl-leucylamide (4-guanido)-butane), Leupeptin (acetyl-leucyl-leucyl-arginal), Antipain ([ $(S)$ -1-carboxy-2-phenyl]-carbamoyl-Arg-Val-arginal), Elastinal ( $N$ -[ $(S)$ -1-carboxy-isopentyl]-carbamoyl- $\alpha$ -(2-iminohexahydro-4( $S$ )-pyrimidyl]-L-glycyl-L-glutaminyl-L-alaninal),  
5 TLCK (tosyllysylchloromethylketone) and TPCK  
(tosylphenylalanylchloromethylketone), for example by introduction of an  
10 asparaginyl residue at an appropriate place in place of an existing amino acid residue.

Vinyl sulphone inhibitors of cysteine proteases are described in Palmer *et al* (1995) *J. Med. Chem.* **38**, 3193-3196. Peptide aldehyde inhibitors of 15 cysteine proteases are described in Thomson *Methods Enzymol.* **46**, 220 - and Vinitsky *et al* (1994) *J. Biol. Chem.* **269**, 29860-29866 639-648. Peptide diazomethanes as inhibitors of cysteine proteases are described in Shaw (1994) *Methods Enzymol.* **244**, 649-656 and Shaw & green (1981) 20 *Methods Enzymol.* **80**, 820-826. Peptide (aryloxy) methanes as inhibitors of cysteine proteases are described in Krantz (1994) *Methods Enzymol.* **244**, 656-671. Peptide N,O-diarylhydroxamates as inhibitors of cysteine proteases are described in Brömme & Demuth (1994) *Methods Enzymol.* 244, 671-685. Peptide chloromethyl ketones as inhibitors of cysteine proteases are described in Williams & Mann (1993) *Methods Enzymol.* 25 **222**, 503-513. Thus, methods for synthesising suitable inhibitors are well known to the person skilled in the art.

are not bound by any theory concerning the invention, we believe that AEP may play an important role in autoimmune disease because it may recognise and cleave at sites which are normally hidden by glycosylation at asparagine residues. Glycosylation at asparagine residues is common in mammalian proteins and glycosylated asparagine residues are not cleaved by AEP. An abnormal reduction in asparagine glycosylation of a self protein may lead to it being susceptible to AEP cleavage at these cryptic sites and, therefore, the peptide produced from the abnormally glycosylated protein may be susceptible to loading into and presentation to the immune system by Class II MHC molecules. Bacterial proteins, such as tetanus toxin, are typically not asparagine glycosylated and so, if they contain appropriate asparagine residues, are susceptible to degradation by AEP and presentation on Class II MHC molecules in any case.

15 Preferably, the diseases are autoimmune diseases and it is particularly preferred if the patient to be treated has or is at risk of an autoimmune disease such as rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, Hashimoto's thyroiditis, coeliac disease, myasthenia gravis, pemphigus vulgaris, systemic lupus erythematosus and Grave's disease.

20 The aforementioned inhibitors for use in the invention or a formulation thereof may be administered by any conventional method including oral, parenteral (eg subcutaneous or intramuscular) injection topical and the like. 25 The treatment may consist of a single dose or a plurality of doses over a period of time.

comprising contacting the cell with an inhibitor of asparaginyl endopeptidase.

- In one embodiment of the invention, a T cell causing a disease, such as 5 one of the autoimmune diseases listed above, is transfected with a pool of cDNAs (or is contacted with proteins expressed from a pool of cDNAs) wherein the pool of cDNAs is believed to contain a cDNA encoding a protein which activates the T cell. The cDNA which encodes a protein which activates the T cell is selected and encodes a putative autoimmune 10 protein. The assay may be carried out in the presence or absence of AEP inhibition in order to determine the involvement of AEP processing in the disease and also to determine any cryptic Asn glycosylation sites which may be important in the self-antigen immune response.
- 15 A further aspect of the invention provides a method of identifying a compound for modulating Class II MHC antigen processing the method comprising contacting a test compound with asparaginyl endopeptidase and selecting a compound which reduces its activity.
- 20 This method (or screening assay) of the invention is suitable carried out in a format which allows for many test compounds to be screened simultaneously such as in a 96-well plate format. The activity of AEP is conveniently measured using any suitable substrate but it is preferred if the substrate is one which, upon cleavage by AEP, gives rise to a readily- 25 detectable product. For example, the product may be coloured or fluorescent or detectable in some other way. It is particularly preferred if the product is fluorescent; a preferred substrate is Z-Ala-Ala-Asn-7-(4-methyl)coumarylamide.

A further aspect of the invention comprises a non-human transgenic animal wherein a gene encoding asparaginyl endopeptidase has been modified and the animal expresses substantially no asparaginyl 5 endopeptidase from said gene.

By "transgenic" animal we specifically include animals in which all or part of a gene have been "knocked out", or otherwise made substantially incapable of expressing an asparaginyl endopeptidase. Suitable mice can 10 be made using standard methodology involving, for example, genetic manipulation of embryonic stem (ES) cells as is well known in the art. A cDNA encoding AEP is described in Chen *et al* (1997) *J. Biol. Chem.* 272, 8090-8096, and this information may be used in designing and making the transgenic animals of the invention.

15

It is particularly preferred if the non-human animal is a mouse, but it may be any suitable non-human animal including rat, rabbit and the like.

In a preferred embodiment of the invention, the non-human transgenic 20 animal which expresses substantially no AEP from an AEP gene comprises a genetic background which predisposes the animal to an autoimmune disease either spontaneously or upon administration of protein antigen. Animals, especially mice, with a suitable genetic background are well known, for example NOD mice, which are a model for diabetes, 25 EAE mice which are a model for allergic encephalomyelitis and CIA mice which are a model for collagen-induced arthritis. Such mice are described or referenced in Cantorna *et al* (1998) *J. Nutr.* 128, 68-72; Xiao & Link

and stained with Coomassie Blue. (b) Cleavage sites: TTGF digestion products were separated by SDS PAGE and electrophoretically transferred to nitrocellulose membrane. Individual fragments numbered 1-6 were subjected to 5 cycles of Edman degradation. N-terminal sequence obtained is shown in bold following upstream residues from TTGF (tetanus toxin numbering). The N-terminal sequence of His-tagged TTGF was obtained for fragments 1 and 3. (c) Residues Asn 1184 and Glu 1184 in TTGF were mutated to alanine (see Methods) and digestions performed as before. The mutation abolishes cleavage at the mutated site but not at the first site (doublet at 47 kD). In this experiment cleavage of the third site was minimal.

**Figure 2:** TTGF is processed by an asparaginyl endopeptidase. (a) Chromatography of the TTGF processing activity on Mono-S resin. Fractions eluted by NaCl gradient were incubated with the substrates Z-Ala-Ala-Asn-NHMec or Z-Phe-Arg-NHMec in the presence or absence of E64 (trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane). E64 had no inhibitory effect on the cleavage of Z-Ala-Ala-Asn-NHMec (not shown). (b) Fractions as above were incubated with 10 µg TTGF in the presence or absence of E64 for 4 hours at 37°C prior to SDS-PAGE analysis. (c) Each fraction was analysed by SDS-PAGE and Western blotting. Electrophoretically transferred material was probed with an affinity purified antiserum raised against the peptide KGIGSGKVLKSGPQC from human legumain<sup>1</sup>.

25

**Figure 3:** Peptide inhibitors of AEP block asparaginyl endopeptidase activity and TTGF processing *in vitro* and *in vivo*. (a) TTGF was digested with purified AEP in the presence or absence of 0.2 mg/ml of the peptides

**Example 1: Asparaginyl endopeptidase is involved in processing and class II MHC presentation of a microbial antigen**

***Summary***

5

Foreign antigens must be proteolytically processed to allow loading of peptides onto class II MHC molecules. To investigate which proteases might be involved we exposed a domain of the microbial antigen, tetanus toxin (TTCF) to disrupted lysosomes purified from a human B cell line.

10

Surprisingly, the dominant processing activity was not one of the known lysosomal cathepsins but rather an asparagine specific cysteine endopeptidase which we call AEP. This enzyme appears similar if not identical to a mammalian homologue of legumain<sup>1</sup>, an asparaginyl endopeptidase found originally in plants and parasites<sup>2,3</sup>. We designed competitive peptide inhibitors of AEP which specifically block its asparaginyl endopeptidase activity and inhibit processing of TTCF *in vitro* and its presentation *in vivo* to T cells. Since N-glycosylation renders asparagine resistant to cleavage by AEP we suggest that this enzyme may represent a further example of the ability of the innate immune system to focus its attention on microbial non-self.

20

To analyse processing of a foreign antigen without making prior assumptions about which enzymes are involved we exposed a 47 kD domain of the tetanus toxin antigen (TTCF) to disrupted lysosomes isolated from the human B cell line EDR. As shown in Fig 1a, the antigen was fragmented to produce a discrete series of products at pH 4.5 but not at pH 7.0 and minimally at pH 6.0, confirming the lysosomal origin of the protease(s) involved (Fig 1a). Surprisingly, we could not

purified the TTGF processing activity from a crude B cell lysosome fraction to establish whether or not it was an asparaginyl endopeptidase. As shown in Figure 2b, a peak of TTGF processing activity eluted from a cation-exchange resin at 0.4M NaCl. This activity co-eluted precisely with an activity capable of cleaving the substrate Z-Ala-Ala-Asn-7-(4-methyl)coumarylamide substrate (Fig 2a). Another protease activity, presumably cathepsin L and/or B, capable of cleaving the substrate Z-Phe-Arg-NHMec, partially overlapped the asparaginyl endopeptidase activity (Fig 2a). However this activity was completely inhibited by E64 (Fig 2a) while both the TTGF and Z-Ala-Ala-Asn-NHMec processing activity were unaffected (Fig 2b) confirming that a novel cysteine endopeptidase was involved. To compare this activity to the recently described mammalian form of legumain we generated anti-peptide antisera to several regions of the mammalian preprolegumain sequence<sup>1</sup>. Blotting of each fraction with an antisera to residues 125-140 (see methods) revealed the presence of a protein with the same mobility (35 kD) as purified pig kidney legumain which co-eluted with the TTGF and peptide substrate processing activity (Fig 2c). Finally, exactly the same processing sites were recognised by the crude lysosomal fraction, the partially purified TTGF processing activity and purified pig kidney legumain (Figs 1b & 2b, ref 1 and data not shown). Thus, mammalian legumain or a closely related enzyme, is present in human B lymphocytes and *in vitro*, is the major enzyme responsible for processing this antigen. We propose the name AEP (Asparaginyl endopeptidase) for this enzyme to distinguish it from the plant enzyme.

We decided to test the possibility that high concentrations of asparagine containing peptides might act as competitive inhibitors. As shown in Fig

simply due to non-specific toxicity. First, presentation to other clones recognising other regions of TTGF was not affected by the AENK competitor (eg AK 111, 71 and 33; Fig 3c). Secondly, there was a clear differential sensitivity to AENK versus AEQK (Fig 3c), strongly suggesting that specific inhibition of AEP was responsible for the slowed kinetics of presentation. Thirdly, the inhibitory effects of AENK could be overridden by using TTGF pre-digested *in vitro* by AEP. In other words, the requirement for AEP *in vivo*, and hence the inhibitory effect of AENK, was by-passed by AEP cleavage *in vitro* (data not shown). Taken together our results reveal AEP as a new and highly specific processing activity in the class II MHC pathway. Preliminary studies show that AEP is present in a variety of other antigen presenting cell types.

Although we uncovered this processing activity using an antigen proteolysis assay, it is possible that it also plays a role in invariant chain processing as well. Splenocytes from cathepsin D gene targeted mice continued to produce invariant chain processing products even when all known cysteine protease activity were also suppressed by leupeptin<sup>7</sup>. Villadangos *et al* suggested that other non-cysteine proteases (besides cathepsin D) must be initiating Ii (invariant chain) cleavage. Cathepsin E is one possible candidate but so too is AEP since, although it is a cysteine protease, it is completely resistant to leupeptin (Fig 1a). Intact p31 Ii is readily cleaved by AEP *in vitro* and we are currently assessing the possibility that AENK also interferes with Ii processing. However, the differential effect of the AENK inhibitor on T cell clones and the fact that pre-digestion of antigen with AEP abolished the inhibitory effect of the AENK inhibitor argues that its primary inhibitory effect in our studies was on TTGF processing.

unbroken cells removed by centrifugation at 2,000 g for 10 minutes. A membrane pellet was collected at 40,000 g and solubilised in 50 mM citrate buffer, pH 5.5 containing 0.1% CHAPS (3-[*cholamidopropyl*]dimethylammonio]-1-propane-sulphonate). The extract was centrifuged at 2,000 g for 20 minutes and then applied to a Mono-S column (Pharmacia[?]). Fractions were eluted with a gradient of NaCl and monitored for TTCF processing activity.

*Proteins and peptides.* A histidine tagged derivative of the C terminal domain of tetanus toxin was prepared<sup>9,10</sup> and purified<sup>10</sup> as described. This protein has residues 872-1315 of the complete toxin (1-1315) preceded by the sequence MGHGHHHHHHHHHSSGHIEGRHI. Mutagenesis of residues 1184/5 was performed using template EH106 obtained by cloning the His-TTCF (Reference 10) as an XbaI/BamHI fragment into pSL1180 (Pharmacia). Site directed mutagenesis of residues 1184/85 was performed according to the method of Mikaelian and Sergent<sup>11</sup> using the mutagenic primer CGC TAC ACT CCG AAC GCG GCG ATC GAT TCT TTC GTT and flanking primers M13 rev (AGCGGATAACAATTTCACACAGGA) and M13 seq (GTAAAACGACGCCAGT). After sequencing to confirm mutagenesis, recloned back into pET16B for expression. Tetrapeptides were synthesised using Fmoc chemistry leaving the C-terminus amidated and the N-terminus retaining the Fmoc group. LHVS was a kind gift from Hidde Ploegh, MIT.

*Antigen presentation.* Peripheral blood mononuclear cells were prepared by Ficoll/Paque centrifugation and used fresh. T cell clones specific for TTCF were established from donor A.K. according to<sup>12</sup>. Epitope

References for Example

1. Chen, J.M., et al (1997) *J. Biol. Chem.* **272**, 8090-8.
2. Kembhavi, A.A., Buttle, D.J., Knight, C.G. & Barrett, A.J. (1993) *Arch. Biochem. Biophys.* **303**, 208-13.
3. Dalton, J.P., Hola Jamriska, L. & Brindley, P.J. (1995) *Parasitology* **111**, 575-80.
4. Riese, R.J., et al (1996) *Immunity* **4**, 357-66.
5. Watts, C. (1997) *Annu Rev Immunol* **15**, 821-50.
6. Fineschi, B. & Miller, J. (1997) *Trends Biochem Sci* **22**, 377-382.
7. Villadangos, J.A., Riese, R.J., Peters, C., Chapman, H.A. & Ploegh, H.L. (1997) *J. Exp. Med.* **186**, 549-60.
8. Davidson, H.W., West, M.A. & Watts, C. (1990) *J Immunol* **144**, 4101-9.
9. Makoff, A.J., Ballantine, S.P., Smallwood, A.E. & Fairweather, N.F. (1989) *Bio/Technology* **7**, 1043-1046.
10. Hewitt, E.W., et al (1997) *J. Immunol.* **159**, 4693-9.
11. Mikelain, I. & Sergent, A. (1992) *Nucleic Acids Res.* **20**, 376.
12. Lanzavecchia, A. (1985) *Nature* **314**, 537-539.
13. Pond, L. & Watts, C. (1997) *J. Immunol.* **159**, 543-53.

**CLAIMS**

1. A method of modulating the immune response in a patient in need of such modulation, the method comprising administering to the patient an effective amount of an inhibitor of asparaginyl endopeptidase.
2. A method according to Claim 1 wherein the patient has or is at risk of a disease which involves MHC Class II molecules.
- 10 3. A method according to Claim 1 or 2 wherein the disease is an autoimmune disease.
4. A method according to Claim 3 wherein the disease is rheumatoid arthritis.
- 15 5. A method according to any one of the preceding claims wherein the inhibitor is a competitive inhibitor.
6. A method according to Claim 5 wherein the competitive inhibitor is a peptide comprising is an asparagine-containing peptide.
- 20 7. A method according to Claim 6 wherein the peptide is an N and C-terminal blocked peptide Ala-Glu-Asn-Lys-NH (AENK) or Lys-Asn-Asn-Glu-NH (KNNE).
- 25 8. A method according to Claim 1 to 4 wherein the inhibitor is a non-competitive or irreversible inhibitor.

14. Use of an inhibitor of asparaginyl endopeptidase in the manufacture of a medicament for modulating the immune response in a patient in need of such modulation.

5

15. Use according to Claim 14 wherein the patient has or is at risk of a disease which involves MHC Class II molecules.

10

16. Use according to Claim 14 or 15 wherein the disease is an autoimmune disease.

17. Use according to Claim 16 wherein the disease is rheumatoid arthritis.

15

18. Use according to any one of Claims 14 to 17 wherein the inhibitor is a competitive inhibitor.

19. Use according to Claim 18 wherein the competitive inhibitor is a peptide comprising is an asparagine-containing peptide.

20

20. Use according to Claim 19 wherein the peptide is an N and C-terminal blocked peptide Ala-Glu-Asn-Lys-NH (AENK) or Lys-Asn-Asn-Glu-NH (KNNE).

25

21. Use according to any one of Claims 14 to 17 wherein the inhibitor is a non-competitive or irreversible inhibitor.

30. A method according to any one of Claims 27 to 29 the method further comprising the step of determining whether the so selected compound is capable of substantially inhibiting the loading and presentation of peptides on an appropriate Class II MHC molecule-containing cell.
- 5
31. A method according to Claim 30 wherein it is determined whether the so selected compound is capable of substantially inhibiting T cell activation by an appropriate Class II MHC molecule-containing cell.
- 10
32. A non-human transgenic animal wherein a gene encoding asparaginyl endopeptidase has been modified and the animal expresses substantially no asparaginyl endopeptidase from said gene.
- 15
33. A non-human transgenic animal according to Claim 32 which is a mouse.
- 20
34. A non-human transgenic animal according to Claim 32 or 33 further comprising a genetic background which predisposes to an autoimmune disease either spontaneously or upon administration of protein antigen.
- 25
35. A non-human transgenic animal according to Claims 32 or 33 further transgenic for a human Class II MHC molecule and, optionally, further transgenic for human CD4.

26-03-98 15:54

01159 552201

26/03 '98 THU 16:00 FAX 01159 552201

22/03 '98 SUN 19:09 FAX 01382 345783

P.39

R-240


Job-974

ERIC POTTER CLARKSON  
WELLCOME TRUST BLD

039  
 01.

Fig 1

Iodoacetamide  
Leupeptin  
E64  
Pepstatin



(b)

Fragment	Sequence/ cleavage site		
1		RHIDN EEDID	EEDID
2,4		YTPNN EDSSF	EIDSF
5		GNAFN NLDRI	NLDRI
6			↑

↑

26-03-98 15:54

01159 552201

26/03 '98 THU 18:00 FAX 01159 552201

22/03 '98 SUN 19:10 FAX 01382 345783

P.40


R-240

Job-974

ERIC POTTER CLARKSON  
WELLCOME TRUST BLD

040  
401

Fig 1c



26-03-98 15:54

01159 552201

26/03 '98 THU 16:00 FAX 01159 552201

22/03 '98 SUN 19:10 FAX 01382 345783

P.41


R-240

Job-974

ERIC POTTER CLARKSON  
WELLCOME TRUST BLD

041  
01

Fig 2



26-03-98 15:54

01159 552201

26/03 '98 THU 16:01 FAX 01159 552201

22/03 '98 SUN 19:10 FAX 01382 345783

P.42


R-240

Job-974

ERIC POTTER CLARKSON  
WELLCOME TRUST BLD

042  
01

Fig 3 a



4/18

26-03-98 15:54

01159 552201

26/03 '98 THU 16:01 FAX 01159 552201

22/03 '98 SUN 19:11 FAX 01382 345783

P.43





R-240

Job-974

ERIC POTTER CLARKSON  
WELLCOME TRUST BLD

043  
011

Fig 3b



518

26-03-98 15:54

01159 552201

26/03 '98 THU 16:01 FAX 01159 552201  
22/03 '98 SUN 19:11 FAX 01382 345783


P.44

R-240

Job-974

ERIC POTTER CLARKSON  
WELLCOME TRUST BLD

044  
001




6/18

fig 3c


# Figure 4 (page 1 of 6)

## Peptide chloromethylketones (ref 5)

(i) Acetyl-tyrosyl-valyl-alanyl-aspariginyl-chloromethylketone  
 (analogous to ICE protease inhibitor YVAD-cmk)




(ii) Acetyl-alanyl-glutamyl-aspariginyl-chloromethylketone



(iii) Acetyl (or benzyloxycarbonyl)-(X)<sub>n</sub>-Aspariginyl-chloromethylketone


Where X = any amino acid




# Figure 4 (page 2 of 6)

Peptidyl diazomethanes (refs 3,4) (have the general structure: R-C(=O)CHN<sub>2</sub>)

(i) benzyloxycarbonyl-leucyl-valyl-asparaginyl-diazomethane




(ii) alanyl-glutamyl-asparaginyl diazomethane



(iii) Z-(X)<sub>n</sub>-asparaginyl-diazomethane

Where BI= acetyl or benzyloxycarbonyl and X= any amino acid




**Figure 4 (page 3 of 6)**

**Peptide vinyl sulphones (ref 6)**

(i) Morpholinurea-leucyl-asparaginyl-vinylsulphone-phenyl


(Acetyl or benzyloxycarbonyl can replace morpholinurea)



$\text{M}_J$  = morpholinurea

(ii) Morpholinurea-alanyl-glutamyl-asparaginyl-vinylsulphone-phenyl

(Acetyl or benzyloxycarbonyl can replace morpholinurea)



(iii) BI-(X)<sub>n</sub>-asparaginyl -vinylsulphone-R

Where BI= N-terminal blocking group (acetyl, morpholinurea or benzyloxycarbonyl, X= any amino acid and R=alkyl or aryl terminating group.





Figure 4 (page 4 of 6)

Peptidyl (acyloxy) methanes (ref 7)


(i) Z-Phenylalanyl-asparaginyl-CH<sub>2</sub>OCO-[2,6-(CF<sub>3</sub>)<sub>2</sub>Phenyl]

(ii) Z-Phenylalanyl-asparaginyl-CH<sub>2</sub>OCO-[2,4,6-(CH<sub>3</sub>) Phenyl]



(iii) Z-alanyl-glutamyl-asparaginyl-CH<sub>2</sub>OCO-[2,6-(CF<sub>3</sub>)<sub>2</sub>Phenyl]

(iv) Z-alanyl-glutamyl-asparaginyl-CH<sub>2</sub>OCO-[2,4,6-(CH<sub>3</sub>) Phenyl]




(iv) Z-(X)n-asparaginyl-CH<sub>2</sub>OCO-R

Where X=any amino acid and R=[2,6-(CF<sub>3</sub>)<sub>2</sub>Phenyl] or [2,4,6-(CH<sub>3</sub>) Phenyl] or other acyloxy methane group


## Figure 4 (page 5 of 6)

N,O-diacyl hydroxamates (ref 8)

(i) Z-Glycyl-asparaginyl-NHO-benzoyl(4-OCH<sub>3</sub>)




(ii) Z-alanyl-glutamyl-asparaginyl-NHO-CO-lysine-NH



(iii) Z-(X)<sub>n</sub>-asparaginyl-NHO-CO-R



Where Z= benzylloxycarbonyl or other blocking group, X= any amino acid, and R= any O-acyl group.




# Figure 4 (page 6 of 6)

Peptide aldehydes (refs 1 & 2) :

(i) Acetyl-leucyl-leucyl-asparignal



(ii) Acetyl-alanyl-glutamyl-asparignal






(iii) Acetyl (or other blocking group)-(X)<sub>n</sub>-Asparignal

—where X denotes any amino acid(s) in peptide linkage.

Elastatinal also blocks AEP. A more specific variant would be:


(iv)



## Figure 5 (page 1 of 6)

E-64

**Structure:** L-trans-epoxysuccinyl-leucylamide-(4-guanido)-butane or  
N-[N-(L-trans-carboxyoxiran-2-carbonyl)-L-leucyl]-agmatine



**Inhibition spectrum:** Irreversible inhibitor of cysteine proteinases. Does not inhibit serine proteinases.

**Mechanism of action:** Forms a thioether bond with the thiol of the active cysteine (1:1 enzyme/inhibitor molar ratio)

**Properties:** E-64 is soluble in aqueous solutions (stock solution 1 mM). Stable from pH 2.0 to pH 10.0 but unstable in ammonia or strong acids, which destroy the epoxide ring. Excellent active-site titrant of cysteine proteinases. Originally isolated from the culture medium of a soil mold, *Aspergillus japonicus*.

MW: 357.4

**Suggested final concentration:** 1-10  $\mu\text{M}$



[Back to PROLYSIS home page](#)


-PDT-

13/18

Figure 5 (page 2 of 6)

## Leupeptin

**Structure:** Acetyl-leucyl-leucyl-arginal



**Inhibition spectrum:** inhibits serine (trypsin ( $K_i=13 \mu M$ ), plasmin, porcine kallikrein) and cysteine proteinases (papain, cathepsin B). Does not inhibit chymotrypsin and thrombin.

**Mechanism of action:** Competitive and reversible inhibitor. Inhibition may be relieved by an excess of substrate.

**Properties:** Soluble in water, ethanol, acetic acid and DMF (Stock solution: 10 mM)  
MW: leupeptin: 426.6; leupeptin hemisulphate monohydrate: 542.7

**Suggested final concentration:** 1-10  $\mu M$  (0.5-1  $\mu g/ml$ )



[Back to PROLYSIS home page](#)


~~052~~

14/18

Figure 5 (page 3 of 6)

## Antipain

Structure: [(S)-1-Carboxy-2-Phenyl]carbamoyl-Arg-Val-arginal



**Inhibition spectrum:** Inhibits papain, trypsin and plasmin to a lesser extent. More specific for papain and trypsin than leupeptin. The inhibitory potency of antipain is 100-fold higher than that of elastatinal.


**Mechanism of action:** Formation of a hemiacetal adduct between the aldehyde group of the inhibitor and the active serine of the proteinase.

**Properties:** Soluble in H<sub>2</sub>O, methanol and DMSO (Stock solution: 10 mM). Stable at -20° C.  
MW: 604.7 for antipain; 677.6 for antipain dihydrochloride

Figure 5 (page 4 of 6)

## Elastatinal

Structure: Leu-(Cap)-Gln-Ala-al,  
N-[(S-1carboxy-isopentyl)-carbamoyl-alpha-(2-iminohexahydro-4(S)-pyrimidyl)]-  
L-glycyl-L-glutaminyl-L-alanine



Inhibition spectrum: Inhibits elastase-like serine proteinases ( $K_i = 0.24 \mu\text{M}$  for porcine pancreatic elastase,  $K_i = 50-80 \mu\text{M}$  for human leukocyte elastase). Specific for elastases, does not inhibit chymotrypsin or trypsin.

Mechanism of action: Formation of a hemiacetal adduct between the aldehyde group of the inhibitor and the active serine of the proteinase.


Properties: Soluble in water (Stock solution: 10 mM)  
MW: 512.6

Suggested final concentration: 10-100  $\mu\text{M}$

# Figure 5 (page 5 of 6)

## TLCK

**Structure:** Tosyl Lysyl ChloromethylKetone:  
1-Chloro-3-tosylamido-7-amino-2-heptanone



**Inhibition spectrum:** Irreversible inhibitor of trypsin. Also inhibits some serine proteases (kallikrein, thrombin, plasmin) and some cysteine proteases such as papain, bromelain or ficin. Does not inhibit chymotrypsin and zymogens.

**Mechanism of action:** Requires an active enzyme and forms a covalent bond with His of the active site. Does not react with zymogens so addition of TLCK in a crude extract inactivates only active protease. Does not react with protease-inhibitor complexes.

**Properties:** TLCK salts are soluble in water up to 20 mg/ml. More stable at pH less or equal to 6.0.  
Soluble up to 5 mg/ml in methanol or to 1 mg/ml in NaCl 0.15 M.  
MW: 369.3 (TLCK.HCl)

**Suggested final concentration:** 50 µg/ml




Back to PROLYSIS home page

~~17/18~~  
17/18

## Figure 5 (page 6 of 6)

## TPCK

**Structure:** Tosyl Phenylalanyl ChloromethylKetone:  
1-Chloro-3-tosylamido-4-phenyl-2-butanone



**Inhibition spectrum:** Irreversible inhibitor of chymotrypsin. Also inhibits some proteases cleaving substrates with a Phe at position P1 and some cysteine proteases such as papain, bromelain or ficin. Does not inhibit trypsin and zymogens.

**Mechanism of action:** Requires an active enzyme and forms a covalent bond with His of the active site. Does not react with zymogens so addition of TPCK in a crude extract inactivates only active protease. Does not react with protease-inhibitor complexes.

**Properties:** TPCK is soluble in ethanol up to 20 mg/ml but poorly in water. It is more stable at slightly acidic or neutral pH. It is destroyed in less than 30 min. at pH 9.0.  
MW: 351.9

**Suggested final concentration:** 100 µg/ml



[Back to PROLYSIS home page](#)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**